The Challenge
Many drugs can be used for multiple diseases beyond their original purpose, a process known as drug repurposing, which accounts for 20-30% of new drug approvals in the U.S.
- Small and large pharmaceutical companies seek to find new uses for their existing drugs, but this process is time-consuming.
- Reviewing existing research to identify new applications can take over four months per disease, making it difficult to analyze multiple drugs simultaneously.
- Today, many decisions are based on limited information and intuition, increasing the risk of errors.
The Solution
An AI-powered engine will allow pharmaceutical companies to generate a shortlist of the 3-5 most promising repurposing projects in just one week.
- AI can screen 40+ potential projects—an impossible task for manual review.
- Since 30% of repurposed drugs gain approval (compared to only 10% for entirely new drugs), a more systematic approach saves time, reduces risks, and accelerates patient access to new treatments.
By leveraging AI, we can calculate a relevance score to determine how effective a treatment is for a new disease—an analysis that typically takes four months manually but only one week with AI.